J&J suing Samsung Bioepis over Stelara biosimilar
Hosted on MSN33m
Samsung Bioepis launches autoimmune disease treatment in U.S.Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, said Tuesday it has launched its biosimilar product ...
GlobalData on MSN18h
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...
Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...
18h
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...
Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...
Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.
Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback